Home
Search Center
Journal List
CMA
Contact US
|
Chinese
You Position:
Home
> Paper
Brain structure development of very pre-term infants on serial cranial ultrasound
( views:0, downloads:0 )
Author:
No author available
Journal Title:
Chinese Medical Journal
Issue:
3
DOI:
10.1097/CM9.0000000000000607
Key Word:
No keyword available
Abstract: No abstract available
Reference
[1]Yi-Hsing,Chen,Wan-Hua,Tsai,Hui-Yu,Wu,etc.
Helicobacter pylori%Lactobacillus%inflammation%probiotic
[J].2019,8(1).
[2]Ping-I Hsu,Pei-Chin Lin,David Y Graham.
Hybrid therapy for Helicobacter pylori infection:A systemic review and meta-analysis
[J].2015,(45).
[3].
Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial
[J].2019,366(sep11_3).
[4]Chuan Han,Zhen Ni,Ting Yuan,etc.
Influence of serum vitamin D level on Helicobacter pylori eradication: A multi‐center, observational, prospective and cohort study
[J].2019,20(8).
[5]Conghua Song,Xing Qian,Yin Zhu,etc.
Effectiveness and safety of furazolidone-containing quadruple regimens in patients with Helicobacter pylori infection in real-world practice
[J].2019,24(4).
[6]J.-C. Delchier,S. Bastuji-Garin,J. Raymond,etc.
Efficacy of a tailored PCR-guided triple therapy in the treatment of Helicobacter pylori infection
[J].2019.
[7]Takahisa,Furuta,Mihoko,Yamade,Takuma,Kagami,etc.
Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori.
[J].2019.
[8]Takara, Yoshimichi,Endo, Hiroyoshi,Nakano, Ryo,etc.
Smoking and Drinking Did Not Increase the Failure of Therapeutic Helicobacter pylori Eradication by Vonoprazan, Clarithromycin, and Amoxicillin
[J].2019,99(2).
[9]Jeerayuth Auttajaroon,Ratha‐,korn Vilaichone,etc.
Once‐daily rabeprazole, levofloxacin, clarithromycin‐MR, and bismuth for Helicobacter pylori eradication: A randomized study of 7 or 14 days (ONCE study)
[J].2019,24(5).
[10]Dong-Min,Yi,Tao-Tao,Yang,Shuai-Heng,Chao,etc.
Comparison the cost-efficacy of furazolidone-based versus clarithromycin-based quadruple therapy in initial treatment of Helicobacter pylori infection in a variable clarithromycin drug-resistant region, a single-center, prospective, randomized, open-label
[J].2019,98(6).
[11]Qi Chen,Xiaohua Long,Yingjie Ji,etc.
Randomised controlled trial: susceptibility‐guided therapy versus empiric bismuth quadruple therapy for first‐line Helicobacter pylori treatment
[J].2019,49(11).
[12]Lu H,Yamaoka Y,Graham DY.
A report card to grade Helicobacter pylori therapy
[J].2007,12(4).
[13]Yong Hwan,Kwon,Seong Woo,Jeon,Su Youn,Nam,etc.
Efficacy of tailored therapy for Helicobacter pylori eradication based on clarithromycin resistance and survey of previous antibiotic exposure: A single-center prospective pilot study.
[J].2019.
[14]Adrian G,McNicholl,Dmitry S,Bordin,Alfredo,Lucendo,etc.
Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients.
[J].2019.
[15]Yang, Jing,Zhang, Yi,Fan, Ling,etc.
Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori
[J].2019,114(3).
[16]Zhiqiang,Song,Wei,Fu,Liya,Zhou.
Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin.
[J].2019,19(1).
[17]Beom Jin Kim,Hyuk Lee,Yong Chan Lee,etc.
Ten-day concomitant, 10-day sequential, and 7-day triple therapy in first-line treatment of Helicobacter pylori infection: a randomized nationwide trial in Korea
[J].2019.
[18]Evgenii I,Olekhnovich,Alexander I,Manolov,Andrey E,Samoilov,etc.
Shifts in the Human Gut Microbiota Structure Caused by Quadruple Helicobacter pylori Eradication Therapy.
[J].2019,10.
[19]Alessia Savoldi,Elena Carrara,David Y. Graham,etc.
Prevalence of Antibiotic Resistance in Helicobacter pylori : A?Systematic Review and Meta-analysis in World Health Organization Regions
[J].2018,155(5).
[20]Adrian G. McNicholl,Colm A. O’,Morain,etc.
Protocol of the European Registry on the management of Helicobacter pylori infection (Hp‐EuReg)
[J].2019,24(5).
[21]Min, Li,Tadayuki, Oshima,Tomoki, Horikawa,etc.
Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori.
[J].2018,(Spec ).
[22]Ben‐,Gang Zhou,Ling‐,etc.
Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta‐analysis with trial sequential analysis
[J].2019,24(5).
[23]Malfertheiner,P.,Megraud,F.,O'Morain,C.A.,etc.
Management of Helicobacter pylori infection - The Maastricht IV/ Florence consensus report
[J].2012,61(5).
[24]Tacconelli, Evelina,Carrara, Elena,Savoldi, Alessia,etc.
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis
[J].2018,18(3).
[25]Jung W,Lee,Nayoung,Kim,Ryoung H,Nam,etc.
Favorable outcomes of culture-based Helicobacter pylori eradication therapy in a region with high antimicrobial resistance.
[J].2019,24(2).
[26]A. Zullo,D. Vaira,N. Vakil,etc.
High eradication rates of Helicobacter pylori with a new sequential treatment
[J].2003,17(5).
[27]Dore, Maria Pina,Lu, Hong,Graham, David Y..
Role of bismuth in improving Helicobacter pylori eradication with triple therapy
[J].2016,65(5).
[28]Angelo,Zullo,Giulia,Fiorini,Giuseppe,Scaccianoce,etc.
Sequential therapy for first-line Helicobacter pylori eradication: 10- or 14-day regimen?
[J].2019,28(1).
[29]Jun‐Hyung Cho,Seong Ran Jeon,Hyun Gun Kim,etc.
Cost‐effectiveness of a tailored Helicobacter pylori eradication strategy based on the presence of a 23S ribosomal RNA point mutation that causes clarithromycin resistance in Korean patients
[J].2019,34(4).
[30]A. T. R. AXON.
V.Helicobacter pyloritherapy: Effect on peptic ulcer disease
[J].1991,6(2).
[31]Xue,Yang,Jin-Xia,Wang,Sheng-Xi,Han,etc.
High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: A systematic review and meta-analysis.
[J].2019,98(7).
[32]Fischbach L,Graham DY.
Helicobacter pylori treatment in the era of increasing antibiotic resistance.
[J].2010,59(8).
[33]Xiaoguang,Shi,Junhong,Zhang,Lingshan,Mo,etc.
Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis.
[J].2019,98(15).
[34]Malfertheiner, P.,Megraud, F.,O'Morain, C. A.,etc.
Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report
[J].2017,66(1).
[35]Hideki,Mori,Hidekazu,Suzuki,Fumio,Omata,etc.
Current status of first- and second-line Helicobacter pylori eradication therapy in the metropolitan area: a multicenter study with a large number of patients.
[J].2019,12.
[36]Mitsushige Sugimoto,Yoshio Yamaoka.
Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan
[J].2019,9.
[37]Andrés,González,Sandra,Salillas,Adrián,Velázquez-Campoy,etc.
Identifying potential novel drugs against Helicobacter pylori by targeting the essential response regulator HsrA.
[J].2019,9(1).
[38]Kagami, T.,Sahara, S.,Ichikawa, H.,etc.
Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype
[J].2016,43(10).
[39]Lili,Wu,Zikai,Wang,Gang,Sun,etc.
Effects of anti-H. pylori triple therapy and a probiotic complex on intestinal microbiota in duodenal ulcer.
[J].2019,9(1).
[40]Saito, Yoshimasa,Konno, Kaho,Sato, Moeka,etc.
Vonoprazan-Based Third-Line Therapy Has a Higher Eradication Rate against Sitafloxacin-Resistant Helicobacter pylori.
[J].2019,11(1).
[41]Lou,Yu,Laisheng,Luo,Xiaohua,Long,etc.
Susceptibility-guided therapy for Helicobacter pylori infection treatment failures.
[J].2019,12.
[42]Jung, Y. S.,Kim, E. H.,Park, C. H..
Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication
[J].2017,46(2).
[43]Lou Yu,Laisheng Luo,Xiaohua Long,etc.
High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: A randomized trial
[J].2019,24(4).
[44]Olga P, Nyssen,Adrian G, McNicholl,Francis, Megraud,etc.
Sequential versus standard triple first-line therapy for Helicobacter pylori eradication.
[J].2016.
[45]Liping Yang,Xinjue He,Lan Li,etc.
Effect of vitamin D on Helicobacter pylori infection and eradication: A meta-analysis
[J].2019,24(5).
[46]Macias-Garcia, Fernando,Baston-Rey, Iria,de la Iglesia-Garcia, Daniel,etc.
Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial
[J].2019,24(1).
[47]Sungmoon Ong,Sung Eun Kim,Ji Hyun Kim,etc.
Helicobacter pylori eradication rates with concomitant and tailored therapy based on 23S rRNA point mutation: A multicenter randomized controlled trial
[J].2019,24(5).
[48]Yao-Bin,Yang-Ou,Yi,Hu,Yin,Zhu,etc.
The effect of antioxidants on Helicobacter pylori eradication: A systematic review with meta-analysis.
[J].2018.
[49]Lei Gu,Shenglan Li,Ying He,etc.
Bismuth, rabeprazole, amoxicillin, and doxycycline as first-line Helicobacter pylori therapy in clinical practice: A pilot study
[J].2019,24(4).
[50]El-Serag, Hashem B.,Kao, John Y.,Kanwal, Fasiha,etc.
Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States
[J].2018,16(7).
[51]Atasoy, Pinar,Guliter, Sefa,Sapmaz, Ferdane,etc.
A Non-Inferiority Study: Modified Dual Therapy Consisting Higher Doses of Rabeprazole Is as Successful as Standard Quadruple Therapy in Eradication of Helicobacter pylori
[J].2017,24(4).
[52]Tongyu,Wang,Xiaoxiao,Yang,Yueyue,Li,etc.
Twice daily short-message-based re-education could improve Helicobacter pylori eradication rate in young population: A prospective randomized controlled study.
[J].2019.
[53]Kapizioni, Christina,Koutoufaris, Georgios,Ntouli, Vasiliki,etc.
Optimal duration of concomitant nonbismuth quadruple therapy as first-line therapy for Helicobacter pylori: a prospective, open-label, comparative study
[J].2019,31(10).
[54]Hu, Y.,Wan, J. -H.,Li, X. -Y.,etc.
Systematic review with meta-analysis: the global recurrence rate of Helicobacter pylori
[J].2017,46(9).
[55]Graham, David Y..
Helicobacter pylori Update: Gastric Cancer, Reliable Therapy, and Possible Benefits
[J].2015,148(4).
[56]Sung Woo,Ko,Yeon-Ji,Kim,Woo Chul,Chung,etc.
Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: Systemic review and meta-analysis.
[J].2019,24(2).
[57]Fang, Hao-Ran,Zhang, Guo-Qiang,Cheng, Jing-Yi,etc.
Efficacy of Lactobacillus-supplemented triple therapy for Helicobacter pylori infection in children: a meta-analysis of randomized controlled trials
[J].2019,178(1).
[58]Crowe, Sheila E..
Helicobacter pylori Infection
[J].2019,380(12).
[59]Bingyun,Lu,Jiamin,Wang,Jing,Li,etc.
Half-dose clarithromycin-containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single-center, open-label, randomized trial.
[J].2019,24(2).
[60]M. Zamani,F. Ebrahimtabar,V. Zamani,etc.
Systematic review with meta‐analysis: the worldwide prevalence of Helicobacter pylori infection
[J].2018,47(7).
[61]Chiba, Naoki,Gisbert, Javier P.,Jones, Nicola L.,etc.
The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults
[J].2016,151(1).
[62].
Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection
[J].2018,23(2).
[63]Vincenzo,De Francesco.
A novel hybrid first-line therapy for H. pylori eradication: results of a pilot study.
[J].2019,28(1).
[64]Soichiro Sue,Wataru Shibata,Tomohiko Sasaki,etc.
Randomized trial of vonoprazan‐based versus proton‐pump inhibitor‐based third‐line triple therapy with sitafloxacin for Helicobacter pylori
[J].2019,34(4).
[65]Qureshi, Nuzhat,Li, Ping,Gu, Qing.
Probiotic therapy in Helicobacter pylori infection: a potential strategy against a serious pathogen?
[J].2019,103(4).
[66]Chey, William D.,Leontiadis, Grigorios I.,Howden, Colin W.,etc.
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection
[J].2017,112(2).
[67]Sugano, Kentaro,Tack, Jan,Kuipers, Ernst J.,etc.
Kyoto global consensus report on Helicobacter pylori gastritis
[J].2015,64(9).
[68]Tsutomu Nishida,Yuri Tsujii,Akino Okamoto,etc.
A Triple-Drug Blister-Packaged Drug with Vonoprazan Improves First-Line Eradication of Helicobacter pylori in Elderly Patients: A Retrospective Propensity Score-Matched Cohort Study
[J].2020,101(5).
[69]Ciccaglione, Antonio Francesco,Cellini, Luigina,Marzio, Leonardo.
Pylera (R) plus ranitidine vs Pylera (R) plus esomeprazole in first-line treatment of Helicobacter pylori infection: Two pilot studies
[J].2019,24(5).
[70]Olga P,Nyssen,Adrian G,McNicholl,Javier P,Gisbert.
Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori.
[J].2019,24(2).
[71]Salillas, Sandra,Alias, Miriam,Michel, Valerie,etc.
Design, Synthesis, and Efficacy Testing of Nitroethylene- and 7-Nitrobenzoxadiazol-Based Flavodoxin Inhibitors against Helicobacter pylori Drug-Resistant Clinical Strains and in Helicobacter pylori-Infected Mice
[J].2019,62(13).
WanfangData CO.,Ltd All Rights Reserved
About WanfangData
|
Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:
yiyao@wanfangdata.com.cn